AU2004286933B2 - Benzoimidazole compounds - Google Patents

Benzoimidazole compounds Download PDF

Info

Publication number
AU2004286933B2
AU2004286933B2 AU2004286933A AU2004286933A AU2004286933B2 AU 2004286933 B2 AU2004286933 B2 AU 2004286933B2 AU 2004286933 A AU2004286933 A AU 2004286933A AU 2004286933 A AU2004286933 A AU 2004286933A AU 2004286933 B2 AU2004286933 B2 AU 2004286933B2
Authority
AU
Australia
Prior art keywords
methyl
benzoimidazole
propoxy
chloro
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004286933A
Other languages
English (en)
Other versions
AU2004286933A1 (en
Inventor
Kristen L. Arienti
J. Guy Breitenbucher
Daniel J. Buzard
James P. Edwards
Michael D. Hack
Haripada Khatuya
David E. Kindrachuk
Alice Lee
Jennifer D. Venable
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2004286933A1 publication Critical patent/AU2004286933A1/en
Application granted granted Critical
Publication of AU2004286933B2 publication Critical patent/AU2004286933B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C04CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04BLIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632Organic additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/53Hinge
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2318/00Antibody mimetics or scaffolds
    • C07K2318/10Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Manufacturing & Machinery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ceramic Engineering (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2004286933A 2003-09-30 2004-09-29 Benzoimidazole compounds Ceased AU2004286933B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50723603P 2003-09-30 2003-09-30
US60/507,236 2003-09-30
PCT/US2004/031855 WO2005044807A2 (en) 2003-09-30 2004-09-29 Benzoimidazole compounds

Publications (2)

Publication Number Publication Date
AU2004286933A1 AU2004286933A1 (en) 2005-05-19
AU2004286933B2 true AU2004286933B2 (en) 2010-11-18

Family

ID=38952593

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004286933A Ceased AU2004286933B2 (en) 2003-09-30 2004-09-29 Benzoimidazole compounds

Country Status (21)

Country Link
US (10) US7432378B2 (https=)
EP (1) EP1673348B1 (https=)
JP (1) JP2007508011A (https=)
KR (1) KR20060097024A (https=)
CN (1) CN1886380B (https=)
AR (1) AR045955A1 (https=)
AT (1) ATE427303T1 (https=)
AU (1) AU2004286933B2 (https=)
BR (1) BRPI0414918A (https=)
CA (1) CA2540704A1 (https=)
DE (1) DE602004020364D1 (https=)
ES (1) ES2323178T3 (https=)
HR (1) HRP20060126A2 (https=)
IL (1) IL174677A0 (https=)
NO (1) NO20061950L (https=)
NZ (1) NZ546259A (https=)
PT (1) PT1673348E (https=)
RU (1) RU2006110561A (https=)
TW (1) TW200526637A (https=)
WO (1) WO2005044807A2 (https=)
ZA (1) ZA200603411B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006110561A (ru) * 2003-09-30 2007-10-10 Янссен Фармацевтика Н.В. (Be) Соединения бензоимидазола
AU2005226729B2 (en) 2004-03-25 2010-01-28 Janssen Pharmaceutica N.V. Imidazole compounds
ES2362102T3 (es) 2004-06-30 2011-06-28 Janssen Pharmaceutica Nv Eteres de bencimidazol e imidazopiridina sustituidos con arilo como agentes anticáncer.
MX2007014881A (es) * 2005-05-26 2008-02-15 Tibotec Pharm Ltd Procedimiento para preparar 4-(1,6-dihidro-6-oxo-2-pirimidinil) amino benzonitrilo.
MX2007016508A (es) * 2005-06-30 2008-03-04 Prosidion Ltd Agonistas del receptor acoplado a la proteina g.
JP5301999B2 (ja) * 2005-10-31 2013-09-25 メルク・シャープ・アンド・ドーム・コーポレーション Cetp阻害薬
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
WO2007069565A1 (ja) * 2005-12-12 2007-06-21 Ono Pharmaceutical Co., Ltd. 二環式複素環化合物
PL2007752T3 (pl) * 2006-03-31 2011-02-28 Janssen Pharmaceutica Nv Benzoimidazol-2-ilopirymidyny i pirazyny jako modulatory receptora histaminowego H4
DE602007008859D1 (de) * 2006-03-31 2010-10-14 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyridine als modulatoren des histamin-h4-rezeptors
WO2007120690A2 (en) * 2006-04-10 2007-10-25 Janssen Pharmaceutica N.V. Combination histamine h1r and h4r antagonist therapy for treating pruritus
FR2903311B1 (fr) * 2006-07-10 2012-06-15 Centre Nat Rech Scient Utilisation de ligands du recepteur h4 de l'histamine pour proteger les progeniteurs hematopoietiques contre la toxicite hematologique des agents chimiotherapeutiques
US7985745B2 (en) 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
WO2009079001A1 (en) 2007-12-18 2009-06-25 Janssen Pharmaceutica N.V. Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine h4 receptor
EP2077263A1 (en) 2008-01-02 2009-07-08 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Quinazolines and related heterocyclic compounds and their therapeutic use
MX2010013727A (es) * 2008-06-12 2011-01-14 Janssen Pharmaceutica Nv Uso de un antagonista h4 de histamina para el tratamiento de adherencias postoperatorias.
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
US20100029942A1 (en) 2008-06-30 2010-02-04 Sergio Cesco-Cancian Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives
US8354400B2 (en) 2008-09-26 2013-01-15 Eisai R&D Co., Ltd. Benzoxazole compounds and methods of use
BRPI0919816A2 (pt) * 2008-09-26 2019-09-24 Eisai R&D Man Co Ltd uso compostos benzoxazólicos no tratamento de malária
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
IT1395137B1 (it) * 2009-08-05 2012-09-05 Spider Biotech S R L Nuovi peptidi antipatogeni
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー CRF−1受容体アンタゴニストとしてのピラゾロ[5,1b]オキサゾール誘導体
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Crf受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
EP2447263A1 (en) 2010-09-27 2012-05-02 Bioprojet Benzazole derivatives as histamine H4 receptor ligands
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
DE102011122420B4 (de) 2011-12-24 2016-07-28 Volkswagen Aktiengesellschaft Verfahren zur Feststellung der Spannungsfreiheit in einem elektrischen Hochvolt-System und ein elektrisches Hochvolt-System
CA2867043A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists
EP2671870A1 (en) * 2012-06-05 2013-12-11 Bioprojet Novel (aza)benzhydryl ether derivatives, their process of preparation and their use as H4-receptor ligands for therapeutical applications
HUE039713T2 (hu) 2012-06-08 2019-02-28 Sensorion H4 receptor inhibitorok tinnitus kezelésére
SMT202000084T1 (it) 2013-03-06 2020-03-13 Janssen Pharmaceutica Nv Modulatori benzoimidazol-2-il pirimidinici del recettore h4 dell'istamina
EP3798212A4 (en) * 2018-05-22 2022-03-23 Nihon Nohyaku Co., Ltd. BENZIMIDAZOLE COMPOUND OR SALT THEREOF, INSECTICIDE AND ACARICIDE FOR AGRICULTURE AND HORTICULTURE WITH THIS COMPOUND AND METHODS OF USE

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026192A1 (de) * 1998-11-03 2000-05-11 Basf Aktiengesellschaft Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung
WO2000068206A1 (de) * 1999-05-07 2000-11-16 Basf Aktiengesellschaft Heterozyklisch substituierte benzimidazole, deren herstellung und anwendung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2587029B1 (fr) * 1985-09-11 1987-10-30 Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
WO1998006703A1 (en) * 1996-08-14 1998-02-19 Warner-Lambert Company 2-phenyl benzimidazole derivatives as mcp-1 antagonists
EP1373204B1 (en) * 2001-03-09 2016-10-26 Janssen Pharmaceuticals, Inc. Heterocyclic compounds
RU2006110561A (ru) * 2003-09-30 2007-10-10 Янссен Фармацевтика Н.В. (Be) Соединения бензоимидазола

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026192A1 (de) * 1998-11-03 2000-05-11 Basf Aktiengesellschaft Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung
WO2000068206A1 (de) * 1999-05-07 2000-11-16 Basf Aktiengesellschaft Heterozyklisch substituierte benzimidazole, deren herstellung und anwendung

Also Published As

Publication number Publication date
RU2006110561A (ru) 2007-10-10
US20090270366A1 (en) 2009-10-29
DE602004020364D1 (de) 2009-05-14
EP1673348A2 (en) 2006-06-28
AU2004286933A1 (en) 2005-05-19
US20050070550A1 (en) 2005-03-31
CA2540704A1 (en) 2005-05-19
KR20060097024A (ko) 2006-09-13
TW200526637A (en) 2005-08-16
NZ546259A (en) 2009-05-31
US7723527B2 (en) 2010-05-25
ES2323178T3 (es) 2009-07-08
AR045955A1 (es) 2005-11-16
ATE427303T1 (de) 2009-04-15
US7432378B2 (en) 2008-10-07
US20090270611A1 (en) 2009-10-29
WO2005044807A2 (en) 2005-05-19
US20090247508A1 (en) 2009-10-01
US7662966B2 (en) 2010-02-16
BRPI0414918A (pt) 2006-11-07
CN1886380B (zh) 2010-12-22
WO2005044807A3 (en) 2005-08-11
US20090270613A1 (en) 2009-10-29
US7723359B2 (en) 2010-05-25
CN1886380A (zh) 2006-12-27
US7723526B2 (en) 2010-05-25
US20090264645A1 (en) 2009-10-22
US20090281307A1 (en) 2009-11-12
US20090264646A1 (en) 2009-10-22
PT1673348E (pt) 2009-05-11
NO20061950L (no) 2006-06-29
US20090275748A1 (en) 2009-11-05
US7705143B2 (en) 2010-04-27
EP1673348B1 (en) 2009-04-01
HRP20060126A2 (en) 2008-05-31
JP2007508011A (ja) 2007-04-05
IL174677A0 (en) 2006-08-20
ZA200603411B (en) 2007-07-25
US20090264647A1 (en) 2009-10-22
US7705149B2 (en) 2010-04-27

Similar Documents

Publication Publication Date Title
AU2004286933B2 (en) Benzoimidazole compounds
JP4767857B2 (ja) ベンゾイミダゾール化合物
US7956066B2 (en) Imidazole compounds
MXPA06003579A (en) Benzoimidazole compounds

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PRIORITY DETAILS FROM US 60/507,231 30 SEPTEMBER 2003 TO US 60/507,236 30 SEPTEMBER 2003

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired